Study details
Enrolling now
Synbiotic Compound to Reduce Symptoms of Schizophrenia
Sheppard Pratt Health System
NCT IDNCT04226898ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Ages
18–65
Locations
1 site in MD
What this study is about
This Phase 2 study is testing Synbiotic Supplement in people with schizophrenia.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
dietary supplement
Endpoints
Secondary: Intestinal Inflammation Markers (#4) C-reactive protein
Body systems
Psychiatry / Mental Health